LOS ANGELES, Oct. 31, 2018 /PRNewswire/ -- Stellar
Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a
key protein utilized in multiple immunotherapy and immuno-oncology
development pipelines, announced today that Stellar President and
CEO Frank R. Oakes will present at
the 10th Annual BlueTech Summit to be held November 5-9, 2018 in San Diego, California.
Mr. Oakes is scheduled to participate in the Biomedicines panel
discussion and presentation on Wednesday,
November 7, 2018 at 2:15 pm Pacific
Time at the InterContinental San Diego hotel.
The conference, which focuses on sustainable ocean and water
technologies, is presented by The Maritime Alliance, a non-profit
organizer of San Diego's BlueTech
cluster and BlueTech Week.
About Stellar Biotechnologies
Based north of Los Angeles at
the Port of Hueneme, Stellar Biotechnologies, Inc. (Nasdaq: SBOT)
is the leader in sustainable manufacture of Keyhole Limpet
Hemocyanin (KLH), an immune-stimulating protein utilized as a
carrier molecule in therapeutic vaccine pipelines (targeting
cancers, immune disorders, Alzheimer's and inflammatory diseases)
and for assessing immune system function. KLH can also be used in
immunotoxicology studies for monitoring the immunomodulatory
effects of drug candidates. Stellar is committed to meeting the
growing demand for commercial-scale supplies of GMP grade KLH,
ensuring environmentally sound KLH production, and supporting the
development of KLH-based active immunotherapies. Stellar KLH is a
trademark of Stellar Biotechnologies.
Follow Stellar: LinkedIn | Twitter | Facebook | Google+
Stellar Forward-Looking Statements
This press release may contain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements may be identified by the use of
words such as "anticipate," "believe," "plan," "estimate,"
"expect," "intend," "may," "will," "would," "could," "should,"
"might," "potential," or "continue" and variations or similar
expressions. Readers should not unduly rely on these
forward-looking statements, which are not a guarantee of future
performance. There can be no assurance that forward-looking
statements will prove to be accurate, as all such forward-looking
statements involve known and unknown risks, uncertainties and other
factors which may cause actual results or future events to differ
materially from the forward-looking statements. Such risks include,
but may not be limited to: general economic and business
conditions; technology changes; competition; changes in strategy or
development plans; availability of funds and resources; anticipated
requirements for operating capital; governmental regulations and
the ability or failure to comply with governmental regulations;
changes in trade policy and international law; the timing of
Stellar's or its partners' anticipated results, including in
connection with clinical trials; the ability to meet the goals of
Stellar's joint ventures and strategic partnerships; and other
factors referenced in Stellar's filings with securities regulators.
For a discussion of further risks and uncertainties related to the
Stellar's business, please refer to Stellar's public company
reports filed with the U.S. Securities and Exchange Commission and
the British Columbia Securities Commission. All forward-looking
statements are made as of the date hereof and are subject to
change. Except as required by law, Stellar assumes no obligation to
update such statements. This press release does not constitute an
offer or solicitation of an offer for sale of any securities in any
jurisdiction, including the United
States.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/stellar-biotechnologies-to-present-at-bluetech-summit-300740933.html
SOURCE Stellar Biotechnologies, Inc.
